CRWD vs TMO: Which Is the Better Buy?
Side-by-side comparison of CrowdStrike Holdings, Inc. and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
CrowdStrike Holdings, Inc. · Technology
$436.32
+106.4% upside to fair value
Grade B
VS
Thermo Fisher Scientific Inc. · Healthcare
$462.60
+10.1% upside to fair value
Grade B
QuantHub Verdict
CRWD has more upside to fair value
(+106.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWD |
TMO |
| Current Price |
$436.32 |
$462.60 |
| Fair Value Estimate |
$900.47 |
$509.20 |
| Upside to Fair Value |
+106.4%
|
+10.1%
|
| Market Cap |
$110.7B |
$171.9B |
| Forward P/E |
-601.6x
|
25.1x
|
| EV / EBITDA |
951.5x
|
19.0x
|
| Price / Sales |
23.0x
|
3.8x
|
| Price / FCF |
89.3x
|
25.5x
|
| Revenue Growth YoY |
+23.3%
|
+6.2%
|
| Gross Margin |
74.9%
|
39.4%
|
| Operating Margin |
-5.4%
|
17.8%
|
| Return on Equity |
-4.7%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.12%
|
3.92%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
CrowdStrike Holdings, Inc. is a leading cybersecurity company specializing in cloud-based endpoint protection and threat intelligence, with a dominant subscription revenue model accounting for over 95% of total revenue. The business quality is medium due to strong revenue growth of 23.3% in the most recent quarter and a robust earnings growth of 141.9% in the same period, supported by a high gros…
Thermo Fisher Scientific Inc. operates in the healthcare sector, specializing in medical diagnostics and research tools across four main segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company demonstrates medium business quality with steady revenue growth of 6.2% and earnings growth of 9.6% in the most recent q…
Accumulation Zones
| Metric |
CRWD |
TMO |
| Zone Low |
$675.35 |
$381.90 |
| Zone High |
$765.40 |
$432.82 |
| In Buy Zone? |
Yes
|
No
|